Abstract
A prospective, non-comparative, single-centre, single-group study was conducted in 50 adult patients with currently remitted recurrent depressive disorder according to the criteria of the International Classification of Diseases, 10th revision in order to assess changes in cognitive function during preventive therapy with fluvoxamine. Responses to therapy were evaluated using the Stroop Color and Word Test as the primary efficacy outcome. The revised Addenbrooke’s Cognitive Examination, Frontal Assessment Battery, Hamilton Rating Scale for Depression and Social Adaptation Self-evaluation Scale were used as secondary indices. Fluvoxamine was administered at doses of 50–150 mg/day for 24 weeks. Fluvoxamine therapy was associated with a range of ‘pro-cognitive’ responses that resulted in improvement in executive functions, including improved voluntary regulation of inhibitory control and restoration of verbal fluency. No dose relation was apparent for these effects. The incidence of treatmentrelated adverse events was low and no serious or severe events were recorded. These findings indicate that further studies of fluvoxamine are warranted and feasible to characterize possible beneficial effects on cognitive processes in patients with depression
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
